Hosted on MSN
Tobramycin + vancomycin no better than vancomycin alone for surgical site infection prevention
WEDNESDAY, April 22, 2026 (HealthDay News) -- The combination of intrawound tobramycin and vancomycin powder is no better than vancomycin powder alone for reducing deep surgical site infection in ...
Drug-induced acute kidney injury (AKI) frequently develops in hospitalized patients receiving nephrotoxic therapy.
Orthopedic surgeons commonly use vancomycin and tobramycin powder intraoperatively to reduce infection risk. A randomized trial showed that adding tobramycin was no better than vancomycin alone at ...
The glycopeptide antibiotics (GPAs) are essential for the control of infectious disease caused by Gram-positive pathogenic bacteria. Three GPAs are in current clinical use (Figure 1 and Table 1): the ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q1 2026 Earnings Call Transcript May 12, 2026 Acurx Pharmaceuticals, Inc. misses ...
Q1 2026 earnings call recap: record revenue, reiterated guidance, CEO transition, 510(k) pipeline updates & key risks.
Adding an extra antibiotic powder doesn't further reduce a person's risk of infection during surgery to repair complex bone fractures, a new study says. People had about the same rate of post-surgery ...
Extra Antibiotic Doesn't Reduce Infection Risk During Surgery To Fix Complex Fractures, Trial Finds By Dennis Thompson HealthDay ReporterMONDAY, April 20, 2026 (HealthDay News) — Adding an extra ...
Clinical Trials Arena on MSN
Lakewood-Amedex reports promising AMR data for Nu-3 in iDFU
Laboratory experiments exposed E. coli and MRSA to Nu-3 for 21 days. The minimum inhibitory concentration (MIC) changed in E. coli, while MRSA showed no change.
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results